FDMT Begin Period Cash Flow from 2010 to 2024
| FDMT Stock | USD 7.50 0.12 1.57% |
Begin Period Cash Flow | First Reported 2019-09-30 | Previous Quarter 275.6 M | Current Value 189.1 M | Quarterly Volatility 90.4 M |
Check 4D Molecular financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among 4D Molecular's main balance sheet or income statement drivers, such as Net Interest Income of 9.6 M, Interest Income of 9.6 M or Depreciation And Amortization of 4.2 M, as well as many indicators such as Price To Sales Ratio of 36.34, Dividend Yield of 0.0 or PTB Ratio of 2.7. FDMT financial statements analysis is a perfect complement when working with 4D Molecular Valuation or Volatility modules.
FDMT | Begin Period Cash Flow |
Latest 4D Molecular's Begin Period Cash Flow Growth Pattern
Below is the plot of the Begin Period Cash Flow of 4D Molecular Therapeutics over the last few years. It is the amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. 4D Molecular's Begin Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in 4D Molecular's overall financial position and show how it may be relating to other accounts over time.
| Begin Period Cash Flow | 10 Years Trend |
|
Begin Period Cash Flow |
| Timeline |
FDMT Begin Period Cash Flow Regression Statistics
| Arithmetic Mean | 54,245,793 | |
| Geometric Mean | 23,569,087 | |
| Coefficient Of Variation | 140.35 | |
| Mean Deviation | 54,329,964 | |
| Median | 7,922,000 | |
| Standard Deviation | 76,132,971 | |
| Sample Variance | 5796.2T | |
| Range | 268.8M | |
| R-Value | 0.64 | |
| Mean Square Error | 3701T | |
| R-Squared | 0.41 | |
| Significance | 0.01 | |
| Slope | 10,861,844 | |
| Total Sum of Squares | 81147.2T |
FDMT Begin Period Cash Flow History
About 4D Molecular Financial Statements
4D Molecular shareholders use historical fundamental indicators, such as Begin Period Cash Flow, to determine how well the company is positioned to perform in the future. Although 4D Molecular investors may analyze each financial statement separately, they are all interrelated. The changes in 4D Molecular's assets and liabilities, for example, are also reflected in the revenues and expenses on on 4D Molecular's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Begin Period Cash Flow | 52.4 M | 103 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for FDMT Stock Analysis
When running 4D Molecular's price analysis, check to measure 4D Molecular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 4D Molecular is operating at the current time. Most of 4D Molecular's value examination focuses on studying past and present price action to predict the probability of 4D Molecular's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 4D Molecular's price. Additionally, you may evaluate how the addition of 4D Molecular to your portfolios can decrease your overall portfolio volatility.